What's Happening?
Galderma announced record net sales of 3.737 billion USD for the first nine months of 2025, marking a 15.0% year-on-year growth at constant currency. The company's growth was driven by volume increases
and favorable product mix across its portfolio, including Injectable Aesthetics and Therapeutic Dermatology. Galderma's strong performance led to an increase in its full-year guidance, with expectations of 17.0-17.7% growth in net sales and a Core EBITDA margin of 23.1-23.6%.
Why It's Important?
Galderma's robust sales growth underscores its leadership in the dermatology sector and its ability to innovate and expand globally. The company's focus on commercial excellence and scientific leadership positions it well for continued growth. The increased guidance reflects confidence in its strategic initiatives and market demand for its products. Galderma's success may influence industry trends and encourage investment in dermatological innovation.
What's Next?
Galderma plans to continue expanding its U.S. operations and investing in manufacturing and infrastructure. The company is also focused on advancing its Therapeutic Dermatology portfolio, particularly Nemluvio, which is driving significant growth. Stakeholders, including healthcare professionals and investors, will likely watch Galderma's progress in executing its growth strategy and maintaining its market leadership.
